Skip to main content

Table 2 Comorbidity and tumor characteristics of patient by initial radiation treatment modality during the 6 months after diagnosis

From: Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer

Comorbidity/tumor characteristics EBRT alone (%)* EBRT+HT (%)* EBRT+BT (%)* EBRT+BT+HT (%)* BT alone (%)* BT+HT (%)* RT (Type unknown)±HT (%)*
Total 24.5 30.4 10.5 7.1 17.9 8.2 1.4
Piccirillo comorbidity score (nw = 8718, p = 0.5183)        
  None 28.5 26.6 31.0 24.6 33.9 26.7 35.3
  Mild 54.4 54.9 55.0 60.2 52.9 60.9 49.3
  Moderate 12.9 14.8 10.5 10.6 10.1 9.1 9.6
  Severe 4.2 3.7 3.5 4.6 3.1 3.3 5.8
PSA (ng/ml) (nw = 8822, p < 0.0001)        
  <10 76.3 52.2 83.0 60.9 92.7 86.3 59.0
  10–20 20.5 25.7 13.6 25.8 5.9 10.1 27.0
  >20 3.2 22.1 3.4 13.3 1.4 3.6 14.0
Clinical T stage (nw = 8941, p < 0.0001)        
  Tx-T0 0.8 0.9 0.0 0.3 0.1 0.4 0.9
  T1 70.5 53.0 66.3 49.4 77.0 79.2 46.7
  T2 27.4 39.2 32.4 45.5 22.9 20.4 44.1
  T3-T4 1.3 6.9 1.3 4.8 0.0 0.0 8.3
Gleason score (nw = 8879, p < 0.0001)        
  2–6 66.7 32.3 56.4 32.6 84.6 76.7 55.1
  7 29.5 42.2 38.0 46.0 14.0 20.7 27.9
  8–10 3.8 25.5 5.6 21.4 1.4 2.6 17.0
Recurrence risk group (nw = 8946, p < 0.0001)        
  LR 46.7 16.5 43.9 15.0 75.4 62.7 31.2
  IR 46.1 41.8 47.3 56.7 21.8 31.4 38.8
  HR 7.2 41.7 8.8 28.3 2.8 5.9 30.0
  1. LR, low risk group; IR, intermediate risk group; HR, high/very high risk group; BT, brachytherapy; EBRT, external beam radiotherapy; HT, hormone therapy.
  2. RT, radiotherapy.
  3. (*) Column percentages based on weighted number of patients, except the first row (Total) which was a row percentage.
  4. (†) p-values (Chi-square test to measure of association between each of comorbidity/tumor characteristics variables and initial treatment modality).